Breaking News

Aptar CSP Launches 3-phase Activ-Polymer Platform

Integrated active packaging solution combines moisture adsorption and oxygen scavenging properties

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptar CSP Technologies has launched the first-of-its kind combination oxygen scavenging and moisture adsorption active packaging solution. This new technology uses the company’s 3-phase Activ-Polymer™ platform within its Activ-Film™ product configuration.

This combination technology builds on the recent U.S. FDA approval of an HIV prevention medicine expected to launch in 1Q20 that uses the company’s Activ-Blister™ packaging solution to provide moisture adsorption and drug product stability.

The company added the combined oxygen scavenging and moisture adsorption capability to the Activ-Film™ product to provide an integrated solution for drug products that are sensitive to both moisture and oxidation. The formulation provides dual protection in various packaging configurations, such as Activ-Blister™, and broad application fields ranging from oral solid dose and transdermal to diagnostics and probiotics.

“This is an important milestone for Aptar CSP as we continue to expand the capabilities of our 3-phase Activ-Polymer™ platform technology to accelerate and de-risk the product development process, providing solutions that improve and save patients’ lives,” said Badre Hammond, Vice President Commercial Operations, Aptar CSP Technologies. “This technology can help reduce packaging complexity while providing a custom solution to stability concerns, enabling pharmaceutical companies to enhance drug stability and support speed-to-market.”

The 3-phase Activ-Polymer™ platform technology offers customized active packaging solutions designed to meet the drug developer’s specific formulation as well as provide a broad spectrum of drug-specific protection, including aroma emitting, volatile organic compounds (VOCs) scavenging, and anti-microbial scavenging.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters